Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC

Annals of Surgical Oncology

Volumn 25, Issue 3, 2018, Pages 702-708

  Reghunathan, Meera ^a   Kelly, Kaitlyn J ^a   Valasek, Mark A ^a   Lowy, Andrew M ^a   Baumgartner, Joel M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR MUCIN; CARCINOEMBRYONIC ANTIGEN; MUCIN; UNCLASSIFIED DRUG;

ADULT; AGED; APPENDIX TUMOR; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; COHORT ANALYSIS; COLLOID CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HEATED INTRAPERITONEAL CHEMOTHERAPY; HIGH GRADE ADENOCARCINOMA; HISTOLOGY; HUMAN; HUMAN CELL; LOW GRADE ADENOCARCINOMA; LOW GRADE APPENDICEAL MUCINOUS NEOPLASM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCINOUS APPENDICEAL TUMOR; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT REFERRAL; PERITONEUM METASTASIS; POSTOPERATIVE COMPLICATION; PREDICTION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURGICAL PATIENT; WORLD HEALTH ORGANIZATION; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; DIAGNOSIS; EPIDEMIOLOGY; MORTALITY; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; REGIONAL PERFUSION; SECONDARY; SURVIVAL RATE; THERMOTHERAPY; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; APPENDICEAL NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85039862723     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-017-6310-8     Document Type: Article

References (23)

1. Shaib WL, Goodman M, Chen Z, et al. Incidence and survival of appendiceal mucinous neoplasms: A SEER analysis. Am J Clin Oncol. 2015;40(6): 569–73.
2. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7970 appendectomies. Dis Colon Rectum. 1998;41(1):75–80.
3. Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol. 2009;33(10):1425–39.
4. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219(2):112–9.
5. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.
6. Austin F, Mavanur A, Sathaiah M, et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol. 2012;19(5):1386–93.
7. Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anatomic Pathol. 2005;12(6):291–311.
8. Davison JM, Choudry HA, Pingpank JF, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014;27(11):1521–39.
9. Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med. 2010;134(6):864–70.
10. Bosman TF, Carniero F, Hruban RH, Theise ND, eds. World health organization classification of tumours of the digestive tract. 4th edn, vol 3. Lyon: IARC Press; 2010.
11. Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol. 2016;40(1):14–26.
12. Carr NJ, Bibeau F, Bradley RF, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71:847–58.
13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
14. Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(5):1716–21.
15. Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228–31.
16. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43 Suppl:S15–25.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990). 2009;45(2):228–47.
18. Enblad M, Birgisson H, Wanders A, Skoldberg F, Ghanipour L, Graf W. Importance of absent neoplastic epithelium in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;23:1149–56.
19. Huang Y, Alzahrani NA, Chua TC, Morris DL. Histological subtype remains a significant prognostic factor for survival outcomes in patients with appendiceal mucinous neoplasm with peritoneal dissemination. Dis Colon Rectum. 2017;60(4):360–7.
20. Winer J, Zenati M, Ramalingam L, et al. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21(5):1456–62.
21. Wagner PL, Austin F, Sathaiah M, et al. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol. 2013;20(2):506–14.
22. Villeneuve L, Isaac S, Glehen O, et al. The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists. Ann Pathol. 2014;34(1):4–8.
23. Valasek MA, Thung I, Gollapalle E, et al. Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care. PLoS ONE. 2017;12(6):e0179216.